BR112013023813A2 - combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson - Google Patents

combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson

Info

Publication number
BR112013023813A2
BR112013023813A2 BR112013023813A BR112013023813A BR112013023813A2 BR 112013023813 A2 BR112013023813 A2 BR 112013023813A2 BR 112013023813 A BR112013023813 A BR 112013023813A BR 112013023813 A BR112013023813 A BR 112013023813A BR 112013023813 A2 BR112013023813 A2 BR 112013023813A2
Authority
BR
Brazil
Prior art keywords
parkinson
disease
alpha
dyskinesia
acetylcholine receptor
Prior art date
Application number
BR112013023813A
Other languages
English (en)
Inventor
Baltazar Gomez-Mancilla
Cristina Lopez-Lopez
Dominik Feuerbach
Donald Johns
Thérése Di Paolo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013023813A2 publication Critical patent/BR112013023813A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson". a presente invenção refere-se a novas combinações adequadas para o tratamento de discinesia associada à terapia de agonista da dopamina na doença de parkinson, as quais compreendem, como ingredientes ativos, pelo menos, um ativador de receptor de acetilcolina nicotínico alfa 7 de baixo peso molecular e, pelo menos, um antagonista de glutamato metabotrópico do receptor 5 de baixo peso molecular, para a sua preparação, à sua utilização como medicamentos e aos medicamentos que os contêm.
BR112013023813A 2011-03-18 2012-03-16 combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson BR112013023813A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161454378P 2011-03-18 2011-03-18
PCT/IB2012/051282 WO2012127393A1 (en) 2011-03-18 2012-03-16 COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE

Publications (1)

Publication Number Publication Date
BR112013023813A2 true BR112013023813A2 (pt) 2016-12-13

Family

ID=45937485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023813A BR112013023813A2 (pt) 2011-03-18 2012-03-16 combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson

Country Status (11)

Country Link
US (1) US20140228398A1 (pt)
EP (1) EP2685977A1 (pt)
JP (1) JP6031458B2 (pt)
KR (1) KR20140018286A (pt)
CN (1) CN103561740A (pt)
AU (1) AU2012232711B2 (pt)
BR (1) BR112013023813A2 (pt)
CA (1) CA2830458A1 (pt)
EA (1) EA201391348A8 (pt)
MX (1) MX2013010698A (pt)
WO (1) WO2012127393A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
KR102318727B1 (ko) 2013-07-31 2021-10-28 노파르티스 아게 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
US6696600B2 (en) * 2001-11-13 2004-02-24 Teva Pharmaceutical Industries, Ltd. L-DOPA ethyl ester salts and uses thereof
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
UA81464C2 (en) 2003-03-04 2008-01-10 NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
CA2551486A1 (en) 2003-12-22 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
RS50603B (sr) 2004-06-01 2010-05-07 F. Hoffmann-La Roche Ag. Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
DK2018380T3 (da) 2006-05-19 2012-01-23 Abbott Lab CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN101568531B (zh) 2006-12-21 2013-11-13 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物
JP2010523587A (ja) * 2007-04-02 2010-07-15 パーキンソンズ インスティテュート 治療処置の副作用の低減のための方法および組成物
MX2009011208A (es) * 2007-04-19 2009-10-30 Novartis Ag Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
MX2010003913A (es) 2007-10-12 2010-04-27 Novartis Ag Moduladores de los receptores de glutamato metabotropicos para el tratamiento de enfermedades de parkinson.
JP2011500673A (ja) 2007-10-19 2011-01-06 アストラゼネカ・アクチエボラーグ 代謝調節型グルタミン酸受容体（ｍｇｌｕｒｓ）の調節因子としてのテトラゾール誘導体
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
AU2009237650B2 (en) * 2008-04-17 2012-05-31 Proximagen Limited Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7
DK2346833T3 (da) 2008-10-13 2013-04-29 Hoffmann La Roche Diazonium-fri fremgangsmåde til fremstilling af et indazolmellemprodukt i syntesen af bicyclisk 5-(trifluormethoxy)-1h-3-indazolcarboxylsyreamider
EP2364150A1 (en) 2008-11-11 2011-09-14 Targacept Inc. Treatment with alpha 7-selective ligands
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102573842A (zh) * 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途

Also Published As

Publication number Publication date
CA2830458A1 (en) 2012-09-27
EA201391348A8 (ru) 2014-11-28
EP2685977A1 (en) 2014-01-22
AU2012232711A1 (en) 2013-10-03
JP6031458B2 (ja) 2016-11-24
MX2013010698A (es) 2014-02-17
US20140228398A1 (en) 2014-08-14
EA201391348A1 (ru) 2014-01-30
KR20140018286A (ko) 2014-02-12
WO2012127393A1 (en) 2012-09-27
CN103561740A (zh) 2014-02-05
AU2012232711B2 (en) 2016-04-28
JP2014508188A (ja) 2014-04-03

Similar Documents

Publication Publication Date Title
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
CY1120089T1 (el) Παραγωγα ουριας ή φαρμακολογικως αποδεκτα αλατα εξ' αυτων χρησιμα ως αγωνιστες του παρομοιου με υποδοχεα πεπτιδιου φορμυλιου 1(fprl-1)
BR112012006346A2 (pt) agonista de receptor de acetilcolina, composto, composição farmacêutica, combinação e uso de ativadores de receptor de acetilcolina nicotínico alfa 7
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
BR112015023142A8 (pt) moduladores do p2x7,seu uso, processo de preparação e composição farmacêutico que os compreende
BR112015013809A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
BR112013027670A2 (pt) "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory"
CR20110509A (es) Composicion farmaceutica
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
BR112012007102A2 (pt) compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014016808A8 (pt) composições de biguanida e métodos de tratamento de distúrbios metabólicos
UY31570A1 (es) Derivados de oxadiazol agonistas del receptor s1p1. composiciones farmacéuticas que lo comprenden y procedimientos de preparacion de los mismos
BR112015014372A2 (pt) inibidores de autotaxina
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112015012730A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
BR112015008954A2 (pt) composições de ciclodextrina alquilatada e processos para preparação e uso das mesmas
BR112013002846A2 (pt) derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112013009004A2 (pt) combinações de agonistas de receptor de serotonina para o tratamento de distúrbios de movimento
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
BR112014017735A8 (pt) Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]